US · Healthcare · Drug Manufacturers - Specialty & Generic
| Fund | Stake |
|---|---|
| Geode Capital Management, LLC | 0.09% |
| Alyeska Investment Group, L.P. | 0.08% |
| Legal & General Group PLC | 0.03% |
| Jane Street Group LLC | 0.02% |
| XTX Topco Ltd | 0.01% |
| Amundi | 0.01% |
| UBS Group AG | 0.01% |
| Quadrature Capital Limited | 0.01% |
| Document | Date |
|---|---|
| Annual report FY2026 (20-F) HEADLINE NUMBERS • Regencell Bioscience Holdings Limited is an early-stage Traditional Chinese Medicine (TCM) bioscience company listed on Nasdaq und | 2026-10-07 |
| Report of foreign private issuer (6-K) · Q2 2026 HEADLINE NUMBERS • Regencell Bioscience Holdings Limited filed a Form 6-K for May 2026. • The filing announces the closing of a registered direct of | 2026-05-22 |
| Report of foreign private issuer (6-K) · Q2 2026 HEADLINE NUMBERS • Regencell Bioscience Holdings Limited plans to sell up to $20,000,000 of ordinary shares. • The purchase price is $20.30 per shar | 2026-05-19 |
| Report of foreign private issuer (6-K) · Q2 2026 HEADLINE NUMBERS • Regencell Bioscience Holdings Limited filed a Form 6-K for May 2026. • The filing announces a registered direct offering of ordin | 2026-05-19 |
| Report of foreign private issuer (6-K) · Q4 2025 HEADLINE NUMBERS • Regencell is an early-stage bioscience company researching and developing Traditional Chinese Medicine (TCM) treatments for ADHD a | 2026-05-08 |
| Annual report FY2025 (20-F) HEADLINE NUMBERS • Fiscal year ended June 30, 2025. • Net loss was $3.58 million, compared with $4.36 million for the fiscal year ended June 30, 202 | 2025-10-31 |
| Annual report FY2024 (20-F) | 2024-10-25 |
| Annual report FY2023 (20-F) | 2023-10-27 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Split | 38 : 1 effective Jun 16, 2025 | 2025-06-16 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Regencell Bioscience Holdings Ltd — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.